Accelerating RNA CTx Development from Bench to Bedside (& Back) for Use in Oncology & Beyond
Time: 2:00 pm
day: Day One
Details:
- Debating optimal pathways to the clinic for RNA CTx and cGMP considerations to assess before embarking on clinical development
- Assessing the best-in-class ways to measure pharmacokinetic and pharmacodynamic properties of RNA CTx
- Highlighting unique safety and toxicology considerations for this class of drugs and the types of animal models to accelerate to the clinic
